Retatrutide is frequently discussed in research involving compound interactions, structured protocols, and multi-pathway study approaches
But state regulators that oversee pharmacies in Louisiana, Mississippi, North Carolina and West Virginia say they are aware that some compounding pharmacists are using a different form of semaglutide that is not approved by the FDA, raising safety concerns
The agency has made it clear that making minor, clinically insignificant changes to a formulation is not a valid way to circumvent the copy designation
Pharmacy availability issues: Users frequently report that their local pharmacy doesn't have Wegovy or Mounjaro in stock, requiring calls to multiple pharmacies or weeks-long waits for supply
SOUL trial (Rybelsus, cardiovascular, October 2024): 9,650 patients with T2D and ASCVD/CKD
doi:10.1056/NEJMoa2500969 Wharton S, Aronne LJ, Stefanski A, et al